Show simple item record

dc.contributor.authorTaylor, Cen_US
dc.contributor.authorCorrea, Cen_US
dc.contributor.authorDuane, FKen_US
dc.contributor.authorAznar, MCen_US
dc.contributor.authorAnderson, SJen_US
dc.contributor.authorBergh, Jen_US
dc.contributor.authorDodwell, Den_US
dc.contributor.authorEwertz, Men_US
dc.contributor.authorGray, Ren_US
dc.contributor.authorJagsi, Ren_US
dc.contributor.authorPierce, Len_US
dc.contributor.authorPritchard, KIen_US
dc.contributor.authorSwain, Sen_US
dc.contributor.authorWang, Zen_US
dc.contributor.authorWang, Yen_US
dc.contributor.authorWhelan, Ten_US
dc.contributor.authorPeto, Ren_US
dc.contributor.authorMcGale, Pen_US
dc.contributor.authorEarly Breast Cancer Trialists’ Collaborative Groupen_US
dc.date.accessioned2017-05-15T14:03:20Z
dc.date.issued2017-05-20en_US
dc.date.submitted2017-04-25T10:41:04.627Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/23112
dc.description.abstractPurpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer radiotherapy versus no radiotherapy in 75 trials yielded rate ratios (RRs) for second primary cancers and cause-specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality. Smoking status was unavailable. Third, the lung or heart ERRs per Gy in the trials and the 2010 to 2015 doses were combined and applied to current smoker and nonsmoker lung cancer and cardiac mortality rates in population-based data. Results Average doses from 647 regimens published during 2010 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart. The median year of irradiation was 2010 (interquartile range [IQR], 2008 to 2011). Meta-analyses yielded lung cancer incidence ≥ 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis of 134 cancers, indicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose. For cardiac mortality, RR was 1.30 (95% CI, 1.15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths. Detailed analyses indicated 0.04 (95% CI, 0.02 to 0.06) ERR per Gy whole-heart dose. Estimated absolute risks from modern radiotherapy were as follows: lung cancer, approximately 4% for long-term continuing smokers and 0.3% for nonsmokers; and cardiac mortality, approximately 1% for smokers and 0.3% for nonsmokers. Conclusion For long-term smokers, the absolute risks of modern radiotherapy may outweigh the benefits, yet for most nonsmokers (and ex-smokers), the benefits of radiotherapy far outweigh the risks. Hence, smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy risk.en_US
dc.description.sponsorshipThis work was funded by core funding to the Clinical Trial Service Unit, University of Oxford from Cancer Research UK, the British Heart Foundation and the Medical Research Council and by the Department of Health, London (project grant RRX 108), Cancer Research UK grant C8225/A21133 and British Heart Foundation Centre of Research Excellence, Oxford grant RE/13/1/30181.en_US
dc.format.extent1641 - 1649en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofJ Clin Oncolen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectFemaleen_US
dc.subjectHearten_US
dc.subjectHeart Diseasesen_US
dc.subjectHumansen_US
dc.subjectLungen_US
dc.subjectLung Neoplasmsen_US
dc.subjectMeta-Analysis as Topicen_US
dc.subjectMiddle Ageden_US
dc.subjectNeoplasms, Radiation-Induceden_US
dc.subjectRadiation Injuriesen_US
dc.subjectRadiotherapyen_US
dc.subjectRadiotherapy Dosageen_US
dc.subjectRandomized Controlled Trials as Topicen_US
dc.subjectRisk Assessmenten_US
dc.titleEstimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.en_US
dc.typeArticle
dc.rights.holder© 2017 by American Society of Clinical Oncology
dc.identifier.doi10.1200/JCO.2016.72.0722en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/28319436en_US
pubs.issue15en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume35en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record